Summit Therapeutics Inc. (SMMT) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Summit Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$15.77
+2.87% today
Market cap
$12.3B
Overall quality
—
Kronos AI 30-day
+0.1%
4 of 8 simulated paths end higher
Summit Therapeutics Inc. (SMMT) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $12.3B. It trades at $15.77, up 2.87% today. 13 analysts' average target of $27.49 implies +74.3% from today's price. Kronos AI's 30-day forecast is +0.1% (4 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $27.49 |
| Low – high | $11.90 – $43.00 |
| Analysts | 13 |
| Upside to average | +74.3% |
Kronos AI 30-day forecast
| Expected close | $15.35 (+0.1%) |
| Likely range | −5.7% … +5.9% |
| As of | 2026-10-27 |
4 of 8 simulated paths end higher.
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.